GSK (GSK) Company Report

GSK has entered into an agreement with the U.S. Administration to lower drug prices and expand access to respiratory medicines for millions of Americans, fulfilling President Trump's four requests.
As part of this agreement, GSK will reduce prices for certain medicines in Medicaid, implement a balanced pricing approach for new products, and offer up to 66% savings on its inhaled respiratory portfolio through a direct purchasing platform.
The agreement also includes securing a U.S. reserve of albuterol and exempts GSK and ViiV Healthcare from s232 tariffs for three years.
Separately, GSK announced in September 2025 plans to invest over $30 billion in U.S. R&D and manufacturing over the next five years, including $2 billion in new investment commitments made in the past 12 months.

3 days ago

6-K

GSK plc announces share repurchase

GSK

Share Buyback

GSK plc repurchased 232,912 ordinary shares on December 19, 2025, through BNP Paribas SA.
The shares were acquired at a volume-weighted average price of 1,807.58p (GBp), with prices ranging from a low of 1,798.50p to a high of 1,818.00p per share.
This transaction is part of an existing buyback program, bringing the total ordinary shares repurchased since September 30, 2025, to 14,554,645.
Following this purchase, the company holds 240,019,489 ordinary shares in treasury, which represents 5.89% of the total voting rights.

4 days ago

6-K

GSK Sells Rockville Facility to Samsung Biologics

GSK

M&A

New Projects/Investments

GSK is selling its Human Genome Sciences facility in Rockville, Maryland, to Samsung Biologics America for $280 million.
The acquisition, which includes two cGMP manufacturing plants with a combined drug-substance capacity of approximately 60,000 liters, is expected to close in the first quarter of 2026.
The deal also involves reported contract manufacturing organization (CMO) contracts valued at about 1.22 trillion won.

4 days ago

Morningstar

GSK Announces Share Buyback

GSK

Share Buyback

GSK plc purchased 235,000 of its ordinary shares on December 17, 2025, as part of its existing buyback program.
The purchase prices ranged from a low of 1,824.00p to a high of 1,850.00p per share, with a volume-weighted average price of 1,841.56p.
These newly acquired shares will be held as treasury shares, increasing the total number of ordinary shares held in treasury to 239,551,577.
Since September 30, 2025, GSK has repurchased a total of 14,086,733 ordinary shares.
Following this transaction, the company has 4,075,889,506 ordinary shares in issue (excluding treasury shares), and the percentage of voting rights attributable to treasury shares is 5.88%.

8 days ago

6-K

GSK announces US FDA approval for Exdensur

GSK

Product Launch

New Projects/Investments

GSK plc announced on December 16, 2025, that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Exdensur is notable as the first and only ultra-long-acting biologic with twice-yearly dosing approved for this patient population.
The approval is based on data from the SWIFT-1 and SWIFT-2 phase III trials, which showed a significant 58% and 48% reduction in the rate of annualised asthma exacerbations over 52 weeks, respectively. A pre-specified pooled analysis also demonstrated a 72% reduction in the annualised rate of clinically significant exacerbations requiring hospitalisation and/or emergency department visits.
Exdensur has also recently received marketing authorisation from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and a positive CHMP opinion in Europe, with an approval decision expected in Q1 2026.

Dec 17, 2025, 12:10 PM

6-K

GSK plc Announces Share Buyback on December 16, 2025

GSK

Share Buyback

GSK plc purchased 230,000 ordinary shares of 31¼ pence each on December 16, 2025, through BNP Paribas SA.
The volume-weighted average price paid per share for this transaction was 1,834.71p.
These newly purchased shares will be held as treasury shares, increasing the total number of ordinary shares held in treasury to 239,316,577.
This transaction is part of an existing buyback programme, under which the company has purchased a total of 13,851,733 ordinary shares since September 30, 2025.
Following this purchase, the percentage of voting rights attributable to the ordinary shares held in treasury is 5.87%.

Dec 17, 2025, 11:31 AM

6-K

GSK's Exdensur (depemokimab) receives US FDA approval for severe asthma

GSK

Product Launch

New Projects/Investments

GSK announced that the US Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older.
Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype.
The FDA approval is based on data from the SWIFT-1 and SWIFT-2 phase III trials, which demonstrated a significant 58% and 48% reduction in the rate of annualized asthma exacerbations over 52 weeks, respectively, compared to placebo.
A pre-specified pooled analysis of the SWIFT trials showed a 72% reduction in the annualized rate of clinically significant exacerbations requiring hospitalization and/or emergency department visits for depemokimab compared with placebo.
Depemokimab recently received a positive CHMP opinion in Europe, with an approval decision expected in Q1 2026, and regulatory submissions are also under review in China and Japan.

Dec 17, 2025, 2:55 AM

Press Release

GSK's Exdensur Receives UK MHRA Approval

GSK

Product Launch

GSK announced that its ultra-long-acting biologic, Exdensur (depemokimab), received marketing authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on December 15, 2025, marking its first global approval.
Exdensur is approved in the UK for two indications: as an add-on maintenance treatment for asthma with type 2 inflammation and as an add-on therapy for severe chronic rhinosinusitis with nasal polyps (CRSwNP).
The approval is based on data from the SWIFT and ANCHOR phase III trials, which showed sustained efficacy with twice-yearly dosing and a 54% reduction in clinically significant asthma exacerbations.
Further regulatory decisions for Exdensur are anticipated in the US, Japan, EU, and China, with approvals expected starting in December 2025 and continuing through H1 2026.

Dec 16, 2025, 1:51 PM

6-K

GSK plc Announces Share Repurchase on December 15, 2025

GSK

Share Buyback

GSK plc repurchased 230,000 ordinary shares on December 15, 2025, as part of its existing buyback programme.
The shares were acquired at a volume-weighted average price of 1,825.73p, with prices ranging from a lowest of 1,810.50p to a highest of 1,838.00p.
These shares will be held as Treasury shares, bringing the total number of ordinary shares held in treasury to 239,086,577.
Since the buyback programme was announced on September 30, 2025, GSK has purchased a total of 13,621,733 ordinary shares.
Following this purchase, the percentage of voting rights attributable to the ordinary shares held in treasury is 5.87%.

Dec 16, 2025, 1:02 PM

6-K

GSK plc Announces Share Buyback on December 12, 2025

GSK

Share Buyback

On December 12, 2025, GSK plc purchased 230,000 ordinary shares of 31¼ pence each through BNP Paribas SA, as part of its existing buyback programme.
The volume-weighted average price paid per share for this transaction was 1,827.59p.
Since September 30, 2025, GSK plc has repurchased a total of 13,391,733 ordinary shares.
Following this purchase, the company will hold 238,856,577 ordinary shares in treasury, representing 5.86% of the total voting rights.

Dec 15, 2025, 12:02 PM

6-K

Earnings Transcripts

Quarterly earnings call transcripts for GSK.

Q3 2025

Oct 29, 2025

→

Q2 2025

Jul 30, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What are GSK's strategic priorities?How is GSK positioned vs competitors?How did GSK do last quarter?